Financial Comparison: AIM ImmunoTech (NYSEAMERICAN:AIM) versus Osiris Therapeutics (OTCMKTS:OSIR)

AIM ImmunoTech (NYSEAMERICAN:AIM) and Osiris Therapeutics (OTCMKTS:OSIR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, risk and dividends.

Profitability

This table compares AIM ImmunoTech and Osiris Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AIM ImmunoTech	-13,360.33%	-1,586.23%	-198.52%
Osiris Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for AIM ImmunoTech and Osiris Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIM ImmunoTech	0	0	1	1	3.50
Osiris Therapeutics	0	0	0	0	0.00

AIM ImmunoTech currently has a consensus target price of $275.00, indicating a potential upside of 10,161.19%. Given AIM ImmunoTech’s stronger consensus rating and higher probable upside, analysts plainly believe AIM ImmunoTech is more favorable than Osiris Therapeutics.

Institutional & Insider Ownership

12.0% of AIM ImmunoTech shares are held by institutional investors. Comparatively, 0.3% of Osiris Therapeutics shares are held by institutional investors. 0.0% of AIM ImmunoTech shares are held by insiders. Comparatively, 43.4% of Osiris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares AIM ImmunoTech and Osiris Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIM ImmunoTech	$170,000.00	42.72	-$17.32 million	($24.68)	-0.11
Osiris Therapeutics	N/A	N/A	N/A	N/A	N/A

Osiris Therapeutics has lower revenue, but higher earnings than AIM ImmunoTech.

Summary

AIM ImmunoTech beats Osiris Therapeutics on 6 of the 10 factors compared between the two stocks.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

About Osiris Therapeutics

Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.